-
11.
公开(公告)号:KR1020140038324A
公开(公告)日:2014-03-28
申请号:KR1020130111137
申请日:2013-09-16
Applicant: (주)셀트리온
IPC: C07D207/12 , A61K31/4015 , A61P35/00
CPC classification number: C07K7/06 , A61K31/40 , A61K31/421 , A61K31/426 , A61K38/00 , C07D207/12 , C07D401/12 , C07D409/12 , C07K5/0205 , C07K5/06052
Abstract: The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method for manufacturing the same, and an anticancer drug composition comprising the same as an active ingredient. The dolastatin-10 derivative of the present invention is a novel synthetic compound which can be used for treating a tumor, slowing growth of tumors, and preventing an increase in number of tumors. For example, the dolastatin-10 derivative is effective to inhibit or prevent the growth of tumor in permalignant and malignant cells.
Abstract translation: 本发明提供具有优异的抗癌活性的多拉司他汀-10衍生物,其制造方法和包含该组合物作为活性成分的抗癌药物组合物。 本发明的多拉司他汀-10衍生物是可用于治疗肿瘤,减缓肿瘤生长和防止肿瘤数量增加的新型合成化合物。 例如,多拉司他汀-10衍生物可有效抑制或阻止去角质和恶性细胞中肿瘤的生长。
-
公开(公告)号:KR101597101B1
公开(公告)日:2016-02-25
申请号:KR1020140000819
申请日:2014-01-03
Applicant: (주)셀트리온
Inventor: 박영준 , 정진교 , 최영미 , 이민섭 , 최준헌 , 이진서 , 조은주 , 송현남 , 박성준 , 이종협 , 이상엽 , 이인숙 , 김준우 , 홍승서 , 김연정 , 김경석
IPC: C07D403/12 , A61K31/4025 , A61K39/395 , A61K47/48 , A61P35/00
Abstract: 본발명은항체의라이신잔기에직접결합할수 있는효소-분해형펩타이드링커를통해항체와세포독성약물이접합된항체-링커-약물결합체, 그의제조방법및 그를유효성분으로포함하는항암제조성물을제공한다.
-